Feature Nuvo Research to release Phase 2 WF10 data in Q1 By Len Zehr Nuvo Research (TSX:NRI) plans to release, in the first quarter of 2015, the results of a confirmatory Phase 2 study for a potential blockbuster allergic rhinitis drug, WF10, which could be a game-changing... December 2, 2014